International Research Journal of Pharmacy and Medical Sciences
ISSN (Online): 2581-3277

Niosome Incorporated Gel for Fungal Disorders: A Review

Ankit Verma[1], S P Srinivas Nayak[2], G S Chakraborthy[3]
[1]Department of Pharmacy Practice, Parul Institute of Pharmacy & Research, Parul University, Vadodara.
[2]Assistant Professor, Department of Pharmacy Practice, Parul Institute of Pharmacy & Research, Parul University, Vadodara.
[3]Prof. and Principal, Parul Institute of Pharmacy & Research, Parul University, Vadodara, Guj
Email address: spnayak843@gmail.com

Abstract*—The skin is an important part of the body because it can be used as a simple and handy site for administering medication. One disadvantage of transdermal drug delivery is the slow rate of medication absorption through the skin. Over the past few decades, nanoparticles have been used as drug delivery systems to increase therapeutic advantages or reduce toxicity. Encapsulating drugs in nanoparticulate vesicles facilitates drug delivery into and through the skin. Niosome nanoparticles are one example of such delivery systems, which are useful for both drug delivery and drug targeting. It is routine practise to load drugs onto niosomes for a wide range of purposes. Recently, niosomal technologies have been the subject of in-depth research on the delivery of antifungal drugs. The efficacy and effectiveness of this nanocarrier in comparison to other nanocarriers can be better understood by analysing the literature on the advantages of niosomes in the administration of antifungal medications*.

***Keywords*—** *Niosome, Nanoparticles, Fungal disorders, Penetration enhancers*.

I. INTRODUCTION

Communicable diseases happen in the peripheral layers of the skin, nails, hair and mucous films. The rate of these contaminations has risen consistently, primarily due to the expanding number of resistant bargained patients and the developing prevalence of gyms and public pools, which encourage the spread of disease. Shallow contagious contaminations incorporate the absolute most every now and again noticed skin infections, influencing a huge number of individuals around the world.[1] Ordinarily, (generally impact in the external layer of the skin) the contaminations brought about by these life forms named for the locales in question. Mouth fungus influences the facial hair zone, fungus corporis happens on the body surface, fungus manuum is restricted to the hands, athlete's foot to the feet and fungus unguium contaminates the toenails. These names do not recognize species. A parasite that attacks the tissue can cause a sickness that is kept to the skin, spreads into tissue, bones and organs or influences the entire body.[2-3]

A. Tinea Corporis: Tinea corporis is alludes to fungus anywhere on the body with the exception of the scalp, facial hair, feet, or hands. This sore presents as an annular plaque with a marginally raised and regularly layered, propelling boundary and is generally known as ringworm. Every sore may have one or a few concentric rings with red papules or plaques in the center. The most common causative agents are Trichophyton rubrum and Trichophyton mentagrophytes.[4] (Regularly Inflammation) As the sore advances, the middle may clear, leaving post-provocative hypopigmentation or hyperpigmentation in humid, crowded circumstances. Sweat excessively because it can create a moist, sticky environment where harmful organisms can thrive. often present in the armpits, crotch creases, and skin folds on the abdomen. Play close-quarters sports like soccer, rugby, or wrestling. Put on poor-airing, constrictive clothing. have a weak, unbreakable structure.[5]



Fig. 1: Tinea Corporis



Fig. 2: Tinea Cruris

B. Tinea Cruris: Tinea cruris also called Jock tingle, is a typical sort of shallow parasitic disease of the crotch area, which is infectious and happens dominatingly however not only in men.[5] It is oftentimes connected with

Ankit Verma, S P Srinivas Nayak, and G S Chakraborthy, "Niosome Incorporated Gel for Fungal Disorders: A Review," *International Research Journal of Pharmacy and Medical Sciences (IRJPMS)*, Volume 7, Issue 5, pp. 104-110, 2024.

(competitor's foot) and contagious nail contaminations.[6] Because it influences the crotch region, fungus cruris also called "athlete tingle." Red scaling plaques on the average thighs and inguinal folds describe it. (generally caused in the human leg or foot and fingers) The plaques are normally respective however typically spare the penis and scrotum, rather than candidiasis.[7]

C. *Tinea Pedis*: It is also called as athlete's foot and it is a typical skin disease of the feet brought about by fungus. Signs and side effects frequently incorporate tingling, scaling, breaking and redness. They may likewise be spread from other animals. T rubrum accounts for approximately 70% of tinea pedis cases, whereas T interdigitale and E floccosum are responsible for the remainder.[8] Usually, conclusion is made dependent on signs and symptoms;(inflammation is occurring regularly or feet skin is eliminating consequently) nonetheless, it very well may be affirmed either by culture or seeing hyphae utilizing a microscope. As erythrasma's coral-red fluorescence is significant for the differential diagnosis of a fungus skin ailment, this light may also be helpful in erythrasma diagnosis.[9]



Fig. 3: Tinea Pedis

II. Introduction to Formulation

Medication zeroing in on is described as the ability to organize a helpful expert at the ideal site of movement with close to zero correspondence with other tissue. Controlled medication conveyance framework is intended to acquire an alluring medication discharge profile for a more drawn-out period. Some different procedures to get controlled delivery framework, one of them is niosome. Ranges between 10 to 1000 nm. It contains quasi, biodegradable, and biocompatible surfactants (more modest and extravagant formulation of the niosome preparation). Niosomes outperform liposomes and have higher surfactant engineered reliability than phospholipid bilayer.[10]

III. Structure of Niosomes

Niosomes are small, lamellar nanostructures that can hydrate in liquid environments, are non-immunogenic, biodegradable, and contain cholesterol. they can also be classified as either alkyl or dialkyl non-ionic polyglycerol ethers.[11] (compared to other avoidable nanoparticles, niosome is the less obvious since this is less obvious.) the hydrophobic completions of the non-ionic agent face each other to create the bilayer, while the hydrophilic cuts are organised to point outward. the identity of molecules is what gives rise to the surfactant's activity. [12]



Fig. 4: Structure of Niosome

IV. Structural Components of Niosomes

The most fundamental component of niosomes is likely its surfactants, which come in a variety of forms and are used to entrap other drugs and form niosomes. the surfactants' lipophilic, bioresorbable, biocompatible, and non-immunogenic qualities, vesicular surface charge, lamellarity, thickness, and the amount of additional substances depend on the targeted niosomes' properties.[12] This bi-layered structure contains a hollow space in the center. Due to their unique geometry, niosomes can contain a hydrophilic drug and a hydrophobic drug in their structure.[13]

1. *Surfactants Linked to Ether*: Hydrophilic and hydrophobic groups associated with ether are produced in two separate reactions by this structural component, polyoxyethylene alkyl ether. Surfactants make up the majority of this group's ingredients, and various surfactants with polyhydroxy heads and ethylene oxide units can also be used to create niosomes.[14]
2. *Ester Linked Surfactants*: The both hydrophilic and hydrophobic moieties are linked by ester bonds. Its role in defining and delivering sodium stibogluconate is examined. [14]
3. *Sorbitan Esters*: These are marketed as sorbitol's incomplete esters, mono- and di-a hydrides, and oleic acid combinations. Different drugs, such as doxorubicin, are used to prepare niosomes.[15]
4. *Alkyl Amides*: Alkyl amides are created by joining alkyl glucosidases and aglycones with amino acid spacers. The alky bunches are partially or entirely saturated with new

Ankit Verma, S P Srinivas Nayak, and G S Chakraborthy, "Niosome Incorporated Gel for Fungal Disorders: A Review," *International Research Journal of Pharmacy and Medical Sciences (IRJPMS)*, Volume 7, Issue 5, pp. 104-110, 2024.

amide compounds with fluorocarbon chains, as well as Carbon-12 to Carbon-22 hydrocarbons.[15]

5. *Fatty Acids and Amino Acid Compounds*: By extending hydrophilic alkyl side chains and long chain trans fats, which are framed by unsaturated fat bilayers in structural vesicles, these amino acids are made amphiphilic.[16]
6. *Cholesterol*: cholesterol, an amphiphilic waxy corticosteroid metabolite, is typically used to add stiffness to non-ionic surfactants. By purposefully mixing steroidal skeleton with surfactants particles in a bilayer, rigidity is produced. Cholesterol is also known to stop the conversion from the gel to fluid phase, which helps to reduce spillage.[17]
7. *Charge Inducers*: These assist in initiating surface properties on the ready vesicles, boost vesicle reliability by preventing vesicle merging brought on by the negative consequences of a comparable charge, and offer more precise zeta potential estimates. Sterylamine and cetyl pyridinium chloride are frequently utilised positive charge inducers, whereas dihexadecyl phosphate and lipoamine corrosive are commonly employed negative charge causers.[18]

V. APPLICATIONS

A drug called iobitridol was developed by Nisomes to use X-rays. Bioactive substance that targets the RES (Reticulo-Endothelial System): A. RES cells preferentially take up the vesicles. Niosomes, which are recognised as flexible by circulating blood components known as opsonins, are also absorbed by the cells. However, this meagre supply of medications has been misused to treat parasite liver invasion and animal cancers that metastasize to the spleen and liver.[19] The To Organ systems, With the exception of RES - Carrier substance can be targeted to particular body parts by utilising antibodies. Immunoglobulins may be effective instruments for focusing the drug transporter because they readily attach to lipid surfaces. Many cells have the natural ability to recognise and bind particular carbohydrates, and this ability can be utilised to direct carriers to particular cells. [20] Anti-neoplastic Therapy: The majority of anti-cancer drugs have detrimental side effects. Niosomes have the potential to modify how well a drug is absorbed, extend its half-life, and prolong its course, all of which decrease the medicine's effectiveness. Niosomes have larger plasma levels and slower clearance, which slow down tumour growth.[21] Leishmaniasis: A parasite from the genus Leishmania attacks the cells of the spleen and the liver to cause leishmaniasis. The effectiveness of the treatment can be increased by utilising higher doses of the medication without experiencing negative side effects, as shown in tests using niosomes. Peptide drug delivery: Peptides can be effectively protected by niosomes from gastrointestinal peptide degradation.[22] An in-vitro investigation has shown that oral delivery of a hormone entrap variants in niosomes boosts the peptide's stability. Because niosomes are immune system-specific, less toxic, and more secure, they are employed to examine immunological response. They frequently consider the idea of a secure reaction brought on by antigens.[23] Non-ionic surfactant vesicles have clearly shown the capacity to act as adjuvants in parenteral injection with a range of antigens and peptides. Cosmetics: L'Oreal's restorative applications were the main source of information about non-ionic surfactant vesicles. In the 1970s and 1980s, L'Oréal created and patented niosomes. Niosome, the company's first product, was launched by Lancôme in 1987. Niosome advantages in skin-care and cosmetic applications include their capacity to improve the bioavailability of chemicals that are difficult to absorb and to enhance skin penetration..[24]

TABLE 1. Advantages and Disadvantages of nisosomes.

Advantage	Disadvantage
Supports a range of prescription medications	Collection
Vesicle characteristics can be modified	Spilling of Entrapped Drug
Controlled and safe medication delivery	Genuine shakiness
No specific circumstances for surfactant control	Monotonous
Regulated drug release	Hydrolysis of encapsulated drugs
Longer oral bioavailability for poorly soluble drugs	Potential titanium probe loss because of the high temperature, high energy consumption
Biodegradable, biocompatible, non-destructive, and non-immunogenic	Macromolecule contamination, solvent or sonication needed, toxicity because of residual organic solvent
Protects drugs from degradation	Not suitable for heat sensitive drug
Prevents drug absorption from stimuli	
Increases formulation tensile strength	
Enhances drug particle supporting profiles and can redesign skin penetration	Instability for long-term usage

VI. METHOD OF PREPARATION

I. *Sonication*: A combination of surfactant, cholesterol, and a pharmaceutical layout in the cradle Niosomes were produced by sonicating a titanium test sample at 60 °C for three minutes..[27]



Fig. 5: Sonication

II. *Ether Injection Method*: Diethyl ether is used to inject niosomes into warm water maintained at 60 degrees Celsius in a solution of surfactant that is steadily present. Through a 14-register needle, combination in ether is combined with a liquid course of material. Ether vaporisation causes the single layer compartments to

Ankit Verma, S P Srinivas Nayak, and G S Chakraborthy, "Niosome Incorporated Gel for Fungal Disorders: A Review," *International Research Journal of Pharmacy and Medical Sciences (IRJPMS)*, Volume 7, Issue 5, pp. 104-110, 2024.

improve. Depending on the usage conditions, vesicles ranges between 50 to 1000 nm.[28-29]



Fig. 6: 'Ether Injection Method'

III. *Using the backward phase evaporation method*: Natural dissolvable surfactant and cholesterol (in a ratio of 1:1) break down (ether and chloroform). Two phases of the water-in-oil emulsion are formed along with the development of the watery medicinal solution for this. The temperature is 4-5oC. At 40 degrees Celsius, the emulsion is dried to form a semisolid gel of huge vesicles. The reasonable gel is mixed with small amounts of phosphorus saline (PBS) and sonicated once. 40°C and lower pressure eliminated the normal stage. Further weakened with phosphorus saline, niosomes are then formed by heating thick niosomal dispersion for 10 minutes at 60°C in a water shower. Technique for Reverse Phase Evaporation.[30]



Fig. 7: Reverse Phase Evaporation Techniques

IV. *The "Bubble" Approach*: To regulate the temperature, a foaming unit with a round-lined cup and three necks is placed in a water shower. Reflux of water-cool located in the main neck. The third neck is where the nitrogen supply is located, and the next neck is where the thermometer is located. At 70 °C, the cushion's pH is 7.4, and cholesterol and surfactant are spread throughout. Using the high-shear homogenizer for 15 seconds while using nitrogen gas and a 70 °C temperature.[31-33]



Fig. 7: Bubble Method

V. Rotating evaporator or slight film dehydration technique for hand shaking Cholesterol and surfactant are the blending ingredients. charge generator in a circular base carafe dissolves in an unpredictably natural solvent (chloroform, diethyl ether, or methanol). Natural dissolvable is dispersed using a rotating evaporator forming a thin layer of strong mixture. With gentle disturbance, the fluid stage at 0-60°C can rehydrate the dry surfactant film. development of niosomes.



Fig.8: Thin Film Hydration technique



Fig. 9: Multiple membrane extrusion method

VI. *Multiple Membranes Extrusion Method*: Dicetyl phosphate, surfactant, and cholesterol are combined in chloroform to form a thin layer that is encircled by a rotating evaporator. Film is hydrated by medication-moistened polycarbonate layers. Up to 8 elements of the arrangement and suspending can be set up for expulsion

Ankit Verma, S P Srinivas Nayak, and G S Chakraborthy, "Niosome Incorporated Gel for Fungal Disorders: A Review," *International Research Journal of Pharmacy and Medical Sciences (IRJPMS)*, Volume 7, Issue 5, pp. 104-110, 2024.

via the polycarbonate layer. It is a logical strategy for controlling niosome size.[35]

VII. *Ethanol Injection Method*: A large amount of saline or other aqueous media is injected into the ethanol surfactant mixture through a fine needle. Vesicle formation as a result of ethanol vaporisation. One method frequently employed to produce liposomes that promote ease of use and wellbeing is ethanol infusion. In this interaction, a water channel is injected with an ethanolic mixture of the needle in the needle, stripping the phospholipids in the medium and causing growth.[36-37]

VIII. *Micro Fluidization*: In the method described in the rule, two fluidized streams connect with one another at extremely high speeds and in tiny channels inside the cooperation chamber. The formation of niosomal compartments with more regularity, controllable size, and higher repeatability is controlled along with regular front in order to guarantee that the energy supplies remain consistent within the region of niosome layout. [38]



Fig. 10: Micro fluidization

VII. NIOSOMAL GEL

Drugs are frequently placed into niosomal compartments, which combine with the appropriate gel base to produce niosomal gel. Potential advantages of novel gel formulations include drug delivery to a specific website, preventing first-pass metabolism, removing medication-induced canal sensitivity, and reducing dosage frequency while maintaining a regulated and long-lasting drug level. Drug-related aspect influence is eliminated through self-administration, direct website distribution, and swift drug action termination.

Accurately weighed amounts of a sterol and an anionic or cationic surface-active agent have been mixed in a chloroform: methanol (2:1) solution and added to a flask with a spherical bottom. After tretinol stock solution and BPO stock solution were added at the desired concentrations (4 mg/ml and 15 mg/ml, respectively) in an optimised surface - active cholesterol quantitative relationship based on batch size, the heat of the tab was set at 60 C, and the flask rotated at a rate of 156 revolutions per minute to fill.[39] Using a rotatory evaporator and a desire fil bottom flask, residue from an organic solvent was removed over the course of twelve hours. In the gift research, water is used as a hydration medium to prepare BPO, and the film was associated with an optimal flow of liquid and saline. Saline and niosomes are employed to prepare the surface agent's lipid transition temperature.

Under a microscope, niosomes were sculpted and identified.[40]



Fig. 11: Niosomal Gel Preparation

VIII. EVALUATION PARAMETERS

Niosome structure and morphology were studied using electron microscopy and transmission electron microscopy (TEM).

a) *Size Specific*: A suspension of niosomes is put onto a glass slide. Niosome suspension was covered with a cover slip, and the standard vesicle size and shape were measured using a common optical magnifying instrument and an utilised visual eyepiece micrometre.[42]

b) *Entrapment Efficiency*: The output of entangled drug-stacked niosomes was resolved after splitting the unentrapped medication, which was performed by freezing spinning at 12,000 rpm for 30 minutes at 4°C. The liquid supernatant accumulated independently.[42] The isolated vesicles were washed in PBS, and the pellet was washed were then mixed with the supernatant liquid. The vesicles were suspended in 3 mL PBS and put in a dialysis bag. The hemodialysis pack was immersed in 200 mL PBS, kept at 37°C, and briefly stirred with a wonderful stirrer after the two closures had been fastened. By using the corresponding criterion, we were able to calculate the quantity of drug that was seized.[43]

c) *In Vitro Release Studies*: The dialysis bag technique, which entailed washing and immersing the sack in distilled water, was used to release niosome suspension in vitro. Pipetting the vesicle solution into a tube bag and then sealing it were the next steps. After that, the fixed quantity was put into a little beaker with 200 mL of phosphate-buffered saline pH 7.4.[43] The tank was placed on a magnetic stirrer and rotated 50 times per minute while maintaining a 37 0.5 C temperature. At regular intervals throughout the experiment, samples were removed and immediately replaced with fresh medium. Drug content analysis using a UV/visible spectrophotometer after sample dilution. [44]

d) *Zeta Potential*: The parameter measures the strength of the electric charges on the lipid bilayer and is used to assess the charge durability of scattered systems like niosomes. a measurement made by passing an electrical charges across

Ankit Verma, S P Srinivas Nayak, and G S Chakraborthy, "Niosome Incorporated Gel for Fungal Disorders: A Review," *International Research Journal of Pharmacy and Medical Sciences (IRJPMS)*, Volume 7, Issue 5, pp. 104-110, 2024.

the sample inside of a capillary flow cell that has been folded.[45]

e) *pH*: In this experiment, 25 cubic centimeter of water contained 2.5 g of carefully weighed gel. The pH of the dispersion was measured using a digital pH metre. The pH of primarily niosomal gel formulations was measured using a digital pH metre. (including the pH articles as well) In 100 cubic centimetres of water, one gramme of gel was dissolved and allowed to sit for two hours.The activity of pH of every formulation was worn out triplicate and average values were calculated by victimization pH Meter.[46]

f) *Viscosity Study*: Victimology Brookfield measuring system used to determine the viscosity of niosomal gel compositions. Gel square rotations are performed at zero. The matching dial reading was noted at 3, 0.6, and 1.5 rotations per minute. The gel's viscosity was calculated by multiplying the dial reading by the problem specified in the poet field context of managing catalogue.[47]

g) *Spreadability:* The flow rate of the niosomal optimized formulation was evaluated using 1 g of gel. A one-centimeter circle with a half-dozen-diameter International analytical Review on Advancing Scientific Hub premark was already on the glass plate that it was placed on top of. A 500 g weight was positioned on the upper glass panel. the enlargement in diameter brought on by gels spreading.[46-47]

h) *Stability Study*: Basic recommendations are outlined for the drug substance intended for icebox storage. in order to determine how stable gels are. The samples were kept intact in tin-foil-wrapped, sealed glass vials. The niosomal in situ gels were maintained at 25 C/60 % + 5% RH for 6 months.[48] The physical features and pure drug gelation temperature of these samples were assessed. Additionally, samples were kept at 5C + 3C for three months. Both the drug content gelling temperature and the physical features of these samples were assessed.[49]

i) *Ex-Vivo Diffusion Study*: For this reason, goat conjunctival epithelium was employed as a sample along with 5ml of frang dispersion cells containing triggered tear fluid. introduced to the donar compartment, a diffusion research was carried out for 6 hours at 37+ 1C, and then the same quality of enhanced tea fluid was removed after 0.5 hours and added once more after 1 hours. [50]

j) Skin Irritation Study: This was carried out on the animal's back by removing the dull and covering the exposed area with 1 cc of sample. It has non-reactive tape covering it. The skin was examined for any irritation 24 to 72 hours after the test sample was applied.[52]

IX. CONCLUSION

Over the past few decades, nanoparticles have been used as drug delivery systems to increase therapeutic advantages or reduce toxicity. Niosome nanoparticles are one of these delivery methods, which have numerous applications in drug development and targeting. The use of niosomes can considerably enhance the intravenous or cutaneous delivery of antifungal drugs. One of the downsides of transdermal medicine administration is the limited penetration rate. The majority of drug concentrations are found in the skin surface, the top layer of skin. Drugs can be more easily delivered through and into skin by being enclosed in nanostructures like niosomes. Niosomes enable the enhancement of medicine absorption through the skin. They could act as natural solvents to aid in the dissolution of insoluble medications. Additionally, niosomes might serve as a regional stockpile for the gradual release of therapeutic agents. The primary rationale for administering niosomes for clinical application via parenteral route include the potential for drug preservation from biological surroundings, the exerting of restricting effects on target tissue, and their prolonged clearance from circulation. According to previous studies, the use of niosomes as drug carriers, especially for antifungal drugs, is more effective than the use of different types of carriers. The capacity to encapsulate equally hydrophilic and hydrophobic medicines, as well as their prolonged stability in circulation, are all major characteristics of niosomes. They also considerably improve drug penetration through the skin. They may be good candidates for the treatment of fungal infections because the materials (mostly clinical) are cheaper than liposomes.

REFERENCES

1. Mujoriya Rajesh, Bodla Ramesh Babu, Dhamande Kishor, Singh Devendra, Patle Lokesh. Niosomal drug delivery system: The magic bullet. Japsonline 01 [09]; 2011: 20- 23
2. Madhav NVS, Saini A. Niosomes: a novel drug delivery system. IJPRC; 2011, 1[3]
3. S Gopalakrishnan, A Chenthilnathan. Niosomes – A novel drug delivery device. RJPBS 2012; 3 [3]: 1090
4. Hawkins DM, Smidt AC. Superficial fungal infections in children. Pediatr Clin North Am. 2014 Apr;61(2):443-55. doi: 10.1016/j.pcl.2013.12.003. Epub 2014 Jan 29. PMID: 24636655.
5. TangriPranshu, Khurana Shaffi. Niosomes formulation and evaluation.IIB, 2011; two [1]: 47-53
6. SankhyanAnchal, PawarPravin. Recent trends in niosome as vesicular drug delivery system.JAPS02 [06]; 2012: 20-32
7. Chauhan S and Luorence MJ. The Preparation of Polyoxyethylene Containing Non-Ionic Surfactant Vesicles. J Pharm. Pharmacol. 1989; 41:6.
8. Yoshioka T, Stermberg B and Florence AT. Preparation and Properties of Vesicles [Niosomes] of Sobitan Monoesters [Span 20, 40, 60, and 80] and a SorbitanTriester [Span 85]. Int J Pharm. 1994; 105:1-6.
9. Gayatri DS, Venkatesh P and Udupa N. Niosomal Sumatriptan Succinate for Nasal Administration. Int J Pharm Sci. 2000; 62[6]:479-481
10. Hu C and Rhodes D.G. Proniosomes: a novel drug carrier preparation. Int J Pharm. 1999; 185:23-35.
11. B.L. Silver Ed., the Physical Chemistry of Membranes, Alan & Unwin and Soloman Press. New York, USA. 1985; 209-230.
12. N.0 Sahin, Niosomes as nanocarrier system, M.R. Mozafari [ed.], Nanomaterials and Nanosystems for Biomedical Applications, 67–81. 2007 Springer
13. Uchegbu IF, Vyas SP. Non-ionic surfactant based vesicles (niosomes) in drug delivery. Int J Pharm. 1998; 172(1-2): 33-70.
14. Saeid Moghassemi, Afra Hadjizadeh, Nano-niosomes as nanoscale drug delivery systems: an illustrated review, J. Contr. Release 185 (2014) 22–36, https://doi. org/10.1016/j.jconrel.2014.04.015.
15. Yoshioka T, Sternberg B, Florence AT. Preparation and properties of vesicles (niosomes) of sorbitan monoesters (Span 20, 40, 60 and 80) and a sorbitantriester (Span 85). Int J Pharm. 1994; 105(1): 1-6.
16. Vora B, Khopade AJ, Jain NK. Proniosome based transdermal delivery of levonorgestrel for effective contraception. J Control Rel. 1998; 54(2): 149-65.

17. Baillie AJ, Florence AT, Hume LR, Muirhead GT, Rogerson A. The preparation and properties of niosomes--non-ionic surfactant vesicles. J Pharm Pharmacol. 1985; 37(12): 863-8.
18. Tamizharasi S, Dubey A, Rathi V, Rathi J. Development and characterization of niosomal drug delivery of gliclazide. J Young Pharmacists. 2009; 1(3): 205-9. Page 26 NIOSOME BASED GEL 26
19. Gupta V, Barupal A, Ramteke S. Formulation development and in vitro characterization of proliposomes for topical Delivery of aceclofenac.
20. D.Krishangopal, Alpana Ram. Niosomes as a novel drug delivery system a review. Int J App Pharm 2013; six [1]: 1-7
21. Desai Sanjeevani, DokeAjit, Disouza John, Athawale Rajani. Development and evaluation of antifungal topical niosomal gel formulation. Int J Pharm Pharm Sci. 2011; 3[5]: 224-231
22. British Pharmacopoeia, London, 2, 2007, 1511.
23. J. H. Draize, G. Woodard, H. O. Calvery. J. Pharmacol. Exp. Ther. 1944, 82(3), 377-390.
24. Shaabani E, Amini SM, Kharrazi S, Tajerian R. Curcumin coated gold nanoparticles: synthesis, characterization, cytotoxicity, antioxidant activity and its comparison with citrate coated gold nanoparticles. Nanomed J. 2017; 4(2):115-25.
25. Abyadeh M, Sadroddiny E, Ebrahimi A, Esmaeili F, Landi FS, Amani A. Electrosprayed chitosan nanoparticles: facile and efficient approach for bacterial transformation. Int Nano Lett. 2017; 7(4):291-5.
26. Firoozi S, Amani A, Derakhshan MA, Ghanbari H. Artificial Neural Networks modeling of electrospun polyurethane nanofibers from chloroform/methanol solution. J Nano Res. 2016; 41:18-30.
27. Osanloo M, Sereshti H, Sedaghat MM, Amani A. Nanoemulsion of Dill essential oil as a green and potent larvicide against Anopheles stephensi. Environ Sci Pollut Res. 2017; 25(7):6466-73.
28. Osanloo M, Amani A, Sereshti H, Abai MR, Esmaeili F, Sedaghat MM. Preparation and optimization nanoemulsion of Tarragon (Artemisia dracunculus) essential oil as effective herbal larvicide against Anopheles stephensi. Indust Crops Prod. 2017; 109:214-9.
29. Akhtari J, Rezayat SM, Teymouri M, Alavizadeh SH, Gheybi F, Badiee A, et al. Targeting, bio distributive and tumor growth inhibiting characterization of anti-HER2 affibody coupling to liposomal doxorubicin using BALB/c mice bearing TUBO tumors. Int J Pharm. 2016; 505(1):89-95.
30. Alavizadeh SH, Akhtari J, Badiee A, Golmohammadzadeh S, Jaafari MR. Improved therapeutic activity of HER2 Affibodytargeted cisplatin liposomes in HER2-expressing breast tumor models. Expert Opin Drug Deliv. 2016; 13(3):325-36.
31. Teymouri M, Badiee A, Golmohammadzadeh S, Sadri K, Akhtari J, Mellat M, et al. Tat peptide and hexadecylphosphocholine introduction into pegylated liposomal doxorubicin: an in vitro and in vivo study on drug cellular delivery, release, biodistribution and antitumor activity. Int J Pharm. 2016; 511(1):236-44.
32. Kelidari HR, Saeedi M, Hajheydari Z, Akbari J, Morteza- Noisome for antifungal drug delivery Osanloo M et al. 36 Curr Med Mycol, 2018, 4(4): 31-36 Semnani K, Akhtari J, et al. Spironolactone loaded nanostructured lipid carrier gel for effective treatment of mild and moderate acne vulgaris: a randomized, double-blind, prospective trial. Biointerfaces. 2016; 146:47-53.
33. Zeng W, Li Q, Wan T, Liu C, Pan W, Wu Z, et al. Hyaluronic acid-coated niosomes facilitate tacrolimus ocular delivery: Mucoadhesion, precorneal retention, aqueous humor pharmacokinetics, and transcorneal permeability. Biointerfaces. 2016; 141:28-35.
34. Behtash A, Nafisi S, Maibach HI. New generation of fluconazole: a review on existing researches and technologies. Curr Drug Delivery. 2017; 14(1):2-15.
35. Soliman OA, Mohamed EA, Khatera NA. Enhanced ocular bioavailability of fluconazole from niosomal gels and microemulsions: formulation, optimization, and in vitro-in vivo evaluation. Pharm Dev Technol. 2017; 2017:1-15.
36. Haque F, Sajid M, Cameotra SS, Battacharyya MS. Anti-biofilm activity of a sophorolipid-amphotericin B niosomal formulation against Candida albicans. Biofouling. 2017; 33(9):768-79.
37. Luiza Ribeiro de Souza A, Priscila Kiill C, Kolenyak dos Santos F, Marielli da Luz G, Rocha e Silva H, et al. Nanotechnology based drug delivery systems for dermatomycosis treatment. Curr Nanosci. 2012; 8(4):512-9.
38. Bayindir ZS, Yuksel N. Characterization of niosomes prepared with various nonionic surfactants for paclitaxel oral delivery. J Pharm Sci. 2010; 99(4):2049-60.
39. Mukherjee B, Patra B, Layek B, Mukherjee A. Sustained release of acyclovir from nano-liposomes and nano-niosomes: an in vitro study. Int J Nanomedicine. 2007; 2(2):213-25.
40. Fang JY, Hong CT, Chiu WT, Wang YY. Effect of liposomes and niosomes on skin permeation of enoxacin. Int J Pharm. 2001; 219(1-2):61-72.
41. Abdelbary G, El-gendy N. Niosome-encapsulated gentamicin for ophthalmic controlled delivery. AAPS PharmSciTech. 2008; 9(3):740-7.
42. McNeil MM, Nash SL, Hajjeh RA, Phelan MA, Conn LA, Plikaytis BD, et al. Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997. Clin Infect Dis. 2001; 33(5):641-7.
43. Maschmeyer G. The changing epidemiology of invasive fungal infections: new threats. Int J Antimicrob Agents. 2006; 27:3-6.
44. Brown GD, Denning DW, Gow NA, Levitz SM, Netea MG, White TC. Hidden killers: human fungal infections. Sci Transl Med. 2012; 4(165):165rv13.
45. Li LX, Jiao J, Wang XB, Chen M, Fu XC, Si WJ, et al. Synthesis, characterization, and antifungal activity of novel benzo[4,5]imidazo[1,2-d][1,2,4]triazine derivatives. Molecules. 2018; 23(4):E746.
46. World Health Organization. WHO model prescribing information: drugs used in skin diseases 1997. Geneva: World Health Organization.
47. Mishra A, Kapoor A, Bhargava S. Proniosomal gel as a carrier for transdermal drug delivery of Clotrimazole. Int J Pharm Sci. 2012; 4:610-4.
48. Chen J, Xu X. Diet, epigenetic, and cancer prevention. In: Herceg Z, Ushijima T, editors. Advances in genetics. Massachusetts: Academic Press; 2010. P. 237-55.
49. Alam M, Zubair S, Farazuddin M, Ahmad E, Khan A, Zia Q, et al. Development, characterization and efficacy of niosomal diallyl disulfide in treatment of disseminated murine candidiasis. Nanomedicine. 2013; 9(2):247-56.
50. Alam M, Dwivedi V, Khan AA, Mohammad O. Efficacy of niosomal formulation of diallyl sulfide against experimental candidiasis in Swiss albino mice. Nanomedicine. 2009; 4(7):713-24.
51. Fetih G. Fluconazole-loaded niosomal gels as a topical ocular drug delivery system for corneal fungal infections. J Drug Deliv Sci Technol. 2016; 35:8-15.
52. Gupta M, Goyal AK, Paliwal SR, Paliwal R, Mishra N, Vaidya B, et al. Development and characterization of effective topical liposomal system for localized treatment of cutaneous candidiasis. J Liposome Res. 2010; 20(4):341-50.
53. Gupta M, Vaidya B, Mishra N, Vyas SP. Effect of surfactants on the characteristics of fluconazole niosomes for enhanced cutaneous delivery. Artif Cells Blood Substit Immobil Biotechnol. 2011; 39(6):376-84.
54. Malhotra M, Jain NK. Niosomes as Drug Carriers. Indian Drugs 1994;31:81-6.

Ankit Verma, S P Srinivas Nayak, and G S Chakraborthy, "Niosome Incorporated Gel for Fungal Disorders: A Review," *International Research Journal of Pharmacy and Medical Sciences (IRJPMS)*, Volume 7, Issue 5, pp. 104-110, 2024.